Active — Not RecruitingPhase 3

A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age

United States5,240 participantsStarted 2025-12-10

Plain-language summary

This study is designed to find out how well the COVID-19 vaccine protects people 50 to 64, who don't have any serious health problems, compared to a group that receives a vaccine that doesn't contain an ingredient to protect against COVID-19 (placebo).

Who can participate

Age range50 Years – 64 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Key Inclusion Criteria * People who are between 50 and 64 years old at their first appointment. * People who are healthy and, based on their medical history and a doctor's judgment, are considered suitable to join the study. Key Exclusion Criteria * People who had COVID-19 in the past 3 months (90 days) before their first visit. * People who got a COVID-19 vaccine, either as part of a research study or an approved vaccine, in the last 3 months-or plans to get one during the study.

What they're measuring

Percentage of participants reporting local reactions or systemic events

Timeframe: From Day 1 up to 7 days after Vaccination

Percentage of participants reporting adverse events

Timeframe: From Day 1 through 4 weeks after vaccination

Percentage of participants reporting serious adverse events

Timeframe: From Day 1 through 6 months after vaccination

First episode of confirmed COVID-19 cases

Timeframe: From 0 days after vaccination through end of COVID-19 surveillance at least 6 months post-vaccination

Trial details

NCT IDNCT07300839

SponsorBioNTech SE

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2026-07-31

View on ClinicalTrials.gov More COVID-19 trials